Literature DB >> 11877049

[Observation of long-term therapeutic outcome in chronic granulocytic leukemia].

B Liu1, Y Wang, C Hao, Y Liu, L Qian.   

Abstract

OBJECTIVE: To analyse the long-term outcome of various therapeutic protocol for the treatment of chronic granulocytic leukemia (CGL).
METHODS: Median duration of chronic phase, survival and transformation of 331 CGL patients treated with different project were retrospectively analyzed. RESULT: Longer chronic phase and survival and lower percentage of transformation were found in patients using mesoindigo as maintaining treatment as compared with those using busulfan as maintaining treatment. The effect of meisoindigo and hydroxyurea showed no significant difference. These two drugs were both superior to bulsufan. Combination chemotherapy was not superior to meisoindigo, hydroxyurea or busulfan alone. Interferon had the best therapeutic effectiveness for the treatment of CGL.
CONCLUSION: Busulfan was not suitable for maintaining treatment. Meisoindigo or meisoindigo combined with hydroxyurea was good choices for maintaining treatment. Meisoindigo and hydroxyurea had better effect in combination than alone. Interferon could significantly prolong the chronic period and survival period of CGL patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11877049

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  Meisoindigo, but not its core chemical structure indirubin, inhibits zebrafish interstitial leukocyte chemotactic migration.

Authors:  Baixin Ye; Xiaoxing Xiong; Xu Deng; Lijuan Gu; Qiongyu Wang; Zhi Zeng; Xiang Gao; Qingping Gao; Yueying Wang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

2.  Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway.

Authors:  Yingze Ye; Tong Jin; Xu Zhang; Zhi Zeng; Baixin Ye; Jinchen Wang; Yi Zhong; Xiaoxing Xiong; Lijuan Gu
Journal:  Front Cell Neurosci       Date:  2019-12-16       Impact factor: 5.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.